CoChat

Mitochondrial Dysfunction Contributes to Oncogene-Induced Senescence

Open access
Moiseeva, Olga, Bourdeau, Véronique, Roux, Antoine, Deschênes-Simard, Xavier, Ferbeyre, Gerardo · 2009 · Molecular and Cellular Biology

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 37 of the 64 sources its claims cite were checked for support.

Abstract

The expression of oncogenic ras in normal human cells quickly induces an aberrant proliferation response that later is curtailed by a cell cycle arrest known as cellular senescence. Here, we show that cells expressing oncogenic ras display an increase in the mitochondrial mass, the mitochondrial DNA, and the mitochondrial production of reactive oxygen species (ROS) prior to the senescent cell cycle arrest. By the time the cells entered senescence, dysfunctional mitochondria accumulated around the nucleus. The mitochondrial dysfunction was accompanied by oxidative DNA damage, a drop in ATP levels, and the activation of AMPK. The increase in mitochondrial mass and ROS in response to oncogenic ras depended on intact p53 and Rb tumor suppression pathways. In addition, direct interference with mitochondrial functions by inhibiting the expression of the Rieske iron sulfur protein of complex III or the use of pharmacological inhibitors of the electron transport chain and oxidative phosphorylation was sufficient to trigger senescence. Taking these results together, this work suggests that mitochondrial dysfunction is an effector pathway of oncogene-induced senescence.

Overview

CoChat Summary

TL;DR

Oncogenic Ras expression in normal human IMR90 fibroblasts increases mitochondrial mass, mtDNA, and mitochondrial ROS before senescence, then leads to depolarized perinuclear mitochondria, oxidative DNA damage, ATP loss, and AMPK activation. These mitochondrial changes require p53 or Rb, and direct mitochondrial interference by RISP knockdown or rotenone/oligomycin is sufficient to trigger senescence, suggesting mitochondrial dysfunction is an effector pathway of oncogene-induced senescence.

Key findings

  • RasV12 induced mitochondrial superoxide by day 2 after selection and higher levels by day 8; mtDNA increased after day 2, and mitochondrial biogenesis genes NRF2a, PGC1α, PGC1β, and TFAM were induced before senescence, with NRF1 increased later.
  • By senescence at day 8, Ras-expressing cells showed perinuclear depolarized mitochondria by JC-1, H2O2 accumulation, 8-OHdG oxidative DNA damage, SOD2/catalase induction by day 6, decreased ATP equivalent to oligomycin treatment, active AMPK, and higher glucose consumption than controls.
  • p53 or Rb was required: shp53 alone or E7 alone did not prevent Ras-induced mitochondrial mass/ROS, E7 partially reduced them, and shp53 plus E7 prevented ROS, mitochondrial mass, and senescence; shp16 with shp53 also prevented these changes, and E1A inhibited Ras-dependent mitochondrial mass/ROS.
  • Direct mitochondrial dysfunction triggered senescence: RISP knockdown caused growth arrest by 6 days with SA-β-Gal, G1 arrest, low BrdU, DNA damage foci, PML bodies, hypophosphorylated Rb, low Mcm6, p21/HDM2 induction, increased ROS/mtDNA, decreased ATP, and AMPK activation; rotenone and oligomycin inhibited growth, with rotenone more efficient at inducing SA-β-Gal, PML bodies, superoxide, and mitochondrial mass.

Methods

  • Normal human diploid IMR90 fibroblasts were infected with retroviral Ha-RasV12 or controls, selected with puromycin, and analyzed at 2 days and 8 days after selection; additional experiments used shRNAs against p53, p16, or RISP, E7, E1A, rotenone, and oligomycin.
  • Assays included qPCR for mtDNA/nuDNA and gene expression; FACS and immunofluorescence for MitoFluor Green, JC-1, MitoSox, DHE, DCFDA, BrdU/PI, SA-β-gal, 8-OHdG, γH2AX, PML, and catalase; Western blotting for AMPK, phospho-AMPK, ACC, p53, p21, HDM2, Ras, Rb, RISP, and tubulin; plus ATP and glucose-consumption measurements.
  • Main analysis compared Ras-expressing versus control cells at pre-senescent and senescent time points, tested p53/Rb pathway requirements, and tested sufficiency of mitochondrial dysfunction via RISP knockdown and mitochondrial inhibitors.

Limitations

  • Stated: the authors cannot eliminate possible contributions of increased cellular ATPase activities or metabolic futile cycles to the ATP drop; the identity and role of perinuclear vacuoles remain to be investigated; it remains challenging to determine whether superoxide production or loss of membrane potential comes first; more studies are required to link p53 and Rb to mitochondria during OIS; further studies are needed for tumor-selective mitochondrial strategies.
  • Stated: antioxidant treatment retarded but did not completely prevent OIS (data not shown).
  • Evident from the text: findings are largely in one normal human fibroblast line (IMR90) with retroviral RasV12, with no in vivo tumor model; several conclusions rely on pharmacological inhibitors and shRNA, and some supporting results are in supplemental figures or not shown.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/mcb.01868-08

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

23 Valid · 1 Not valid · 13 Not checked · 95 Own results and interpretations

70 more claims · 4 with their cited sources checked

Create a free account to see all 132 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 38

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

Items 401–407 of 407

Metadata

Authors
Moiseeva, O., Bourdeau, V., Roux, A., Deschênes-Simard, X., & Ferbeyre, G.
Affiliations
  • Université de Montréal (CA)
  • Département de Biochimie, Université de Montréal, C.P. 6128, Succ. Centre-Ville, Montréal, Québec H3C 3J7, Canada
Venue
Molecular and Cellular Biology
Published
2009-08-01
Volume
29
Issue
16
Pages
4495-4507
ISSN
  • 0270-7306 (ISSN-L)
  • 1098-5549
OpenAlex
W2007244362
Cited by
408
References
52
Citations by year
2026: 15 · 2025: 27 · 2024: 28 · 2023: 32 · 2022: 29 · 2021: 28 · 2020: 36 · 2019: 28 · 2018: 25 · 2017: 22 · 2016: 25 · 2015: 16 · 2014: 25 · 2013: 12 · 2012: 22
FWCI
13.25
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Molecular and Cellular Biology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
oncogene-induced senescence, mitochondrial dysfunction, oncogenic Ras, reactive oxygen species, mitochondrial DNA, oxidative DNA damage, AMPK activation, p53, Rieske iron-sulfur protein, electron transport inhibition, oxidative phosphorylation, ATP depletion, mitochondrial mass
MeSH terms
Adenylate Kinase, Animals, Cell Cycle, Cell Line, DNA Damage, Enzyme Activation, Humans, Mitochondria, Genes, ras, Electron Transport Complex III, Cellular Senescence, Reactive Oxygen Species, Oxidative Stress, ras Proteins, Gene Expression Profiling, Genes, Mitochondrial, Membrane Potential, Mitochondrial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.